CUE-221 Shows Dose-Consistent Activity in Chinese Urticaria Study

Company Cue Biopharma Event Type Phase 2 Clinical Readout Modality Humanized IgG1 Anti-IgE Antibody Asset CUE-221 (UB-221) Target Free IgE (Preserving IgE-CD23 Engagement) Disease Area Chronic Spontaneous Urticaria Summary Cue Biopharma disclosed positive topline results from a 145-participant randomized double-blind Phase 2 study of CUE-221,…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring
Sobi Licenses Lacutamab in $580 Million Deal
Moonwalk Raises $70 Million for Adipose-Targeted RNAi
Neomorph – $100M Molecular Glue Financing